FindMyKOL
Clinical trialNCT05349292RecruitingObservational

Acute Normovolemic Hemodilution on Urine Neutrophil Gelatinase-associated Lipocalin Levels

NCT05349292 is an observational study sponsored by University of Maryland, Baltimore. As of 18 Nov 2026, it is recruiting participants. It studies Acute Kidney Injury. The registry lists an enrollment of 100 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2024 and a primary completion date of 30 Jun 2027.

SponsorUniversity of Maryland, Baltimore →Enrollment100Acute Kidney Injury
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05349292
FieldValue
Registry IDNCT05349292
StatusRecruiting
Study typeObservational study
Lead sponsorUniversity of Maryland, Baltimore
Enrollment100
Registered sites1
Countries1
ConditionsAcute Kidney Injury
Start31 Jan 2024
Primary completion30 Jun 2027
Study completion31 Dec 2027
Last update posted1 May 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Acute normovolemic hemodilution (ANH) is performed as a blood conservation technique during surgical procedures with high risk for significant blood loss. It is done by taking out some of the patients blood before surgery actually begins and storing this blood inside of the operating room and giving it back to the patient at the end of surgery when most of the expected surgical bleeding has already occurred. This practice reduces the amount of bleeding that occurs after surgery and also reduces the amount of blood transfusions given to the patient after surgery. Transfusion of blood products from the blood bank may cause problems such as transfusion reactions and infections like hepatitis, and also increases cost. 3 meta-analyses and several smaller trials have shown improvement in blood transfusion rates with the use of ANH, however there is no evidence of improvement in other complication rates, morbidity and mortality, length of stay or cost. In most types of surgery, when ANH is done, large volumes of IV fluids are given to the patient to prevent a drop in circulatory volume and blood pressure. However during heart surgery, this can cause significant levels of hemodilution in addition to that caused by use of the heart-lung machine. In order to minimize hemodilution when ANH is performed during heart surgery, a smaller amount of IV fluids are given to the patient after blood is drawn. Vasoactive medications are then administered to prevent the blood pressure from dropping. Kidney injury is a recognized complication that may occur after heart surgery. It may be caused by low blood volume, low blood pressure and anemia. It is not known whether performance of ANH and use of the heart-lung machine may increase risk for kidney injury. Kidney injury is associated with increased risk for other medical complications and death. This increased risk for kidney injury arising from ANH has not been evaluated. This study will therefore compare patients treated with ANH to those not treated with ANH to determine whether there is an increased risk for kidney injury with the use of ANH.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Maryland, United States1 site, 1 recruiting
  • University of Maryland Medical Center

    Baltimore

    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 site, 1 recruitingMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT05349292

Each answer restates registry values shown on this page.

What is NCT05349292?

NCT05349292 is an observational study sponsored by University of Maryland, Baltimore. It studies Acute Kidney Injury.

Is NCT05349292 recruiting?

As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT05349292?

The registry names Patrick Odonkor, MD (principal investigator, University of Maryland, Baltimore) as the overall official.

Where does NCT05349292 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When is NCT05349292 expected to complete?

The registry lists a primary completion date of 30 Jun 2027 and a study completion date of 31 Dec 2027. The sponsor last updated the record on 1 May 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.